Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Sorafenib 400 mg twice daily demonstrated activity and a clinically acceptable toxicity profile in all patient subsets enrolled in the ARCCS expanded access program (clinicaltrials.gov identifier: NCT00111020).